To advance academic exchange in the field of lymphoma and enhance the clinical practice capabilities of healthcare professionals in lymphoma diagnosis and treatment, the "Cancer Prevention and Control City Development Plan & CD20 Monoclonal Antibody and Lymphoma Diagnosis and Treatment: Case Sharing and Expert Insights," organized by the Chengdu High-Tech Medical Association, was successfully held in Kunming on March 10, 2025. The event brought together renowned experts from across the region to delve into key topics such as the optimal selection of CD20 monoclonal antibodies, cutting-edge advancements in lymphoma treatment, and clinical challenges. It aimed to provide medical professionals with a high-quality platform for learning and experience exchange. Colleagues from various institutions were invited to gather and contribute to this academic feast, collectively driving lymphoma diagnosis and treatment to new heights.

       The conference integrated authoritative expert insights, case discussions, and the latest academic trends, offering attendees practical guidance on the clinical application of CD20 monoclonal antibodies. In-depth discussions on personalized treatment strategies for lymphoma and the management of complex cases further contributed to elevating the comprehensive cancer prevention and treatment capabilities of medical institutions at all levels.